ARCTURUS THERAPEUTICS, INC., a Delaware corporation (Delaware file no.: [[Identifier]]) located at 10628 Science Center Drive, Suite 250, San Diego, California 92121, USA, as the company (the "Company"); and

INSYS THERAPEUTICS, INC. and RENAISSANCE entered into a Manufacturing Agreement dated May 24, 2011, as amended October 29, 2013 (“Amendment No. 1”), April 30, 2015 (“Amendment No. 2”), August 18, 2015 (“Amendment No. 3”), July 14, 2016 (“Amendment No. 4”) and April 10, 2018 (“Amendment No. 5” and as amended, the “Manufacturing Agreement”) for the supply of Product (as defined below).

INSYS THERAPEUTICS, INC. and RENAISSANCE entered into a Manufacturing Agreement dated May 24, 2011, as amended October 29, 2013 (“Amendment No. 1”), April 30, 2015 (“Amendment No. 2”), August 18, 2015 (“Amendment No. 3”) and July 14, 2016 (“Amendment No. 4”, and as amended, the “Manufacturing Agreement”) for the supply of Product.

Five Prime Therapeutics, Inc. 111 Oyster Point Boulevard South San Francisco, CA 94080 Attention: General Counsel

Five Prime Therapeutics, Inc. • 111 Oyster Point Boulevard • South San Francisco, CA 94080 • Phone [[Phone]] • Fax [[Phone]]

SUBLANDLORD: Five Prime Therapeutics, Inc., a Delaware corporation By: /s/ Thomas Civik Name: Thomas Civik Its: President and Chief Executive Officer

SUBLANDLORD: Five Prime Therapeutics, Inc., a Delaware corporation By: /s/ [[Person A:Person]] Name: [[Person A:Person]] Its: President and Chief Executive Officer

Tenant: Civitas Therapeutics, Inc., a Delaware corporation

Arcturus Therapeutics Holdings Inc. is more than thirty (30) days delinquent with respect to its quarterly and annual filings required under applicable US securities laws;

THIS SUBLEASE (this “Sublease”) is made and entered into this 3rd day of September, 2020, by and between Five Prime Therapeutics, Inc., a Delaware corporation (“Sublandlord”), and Sutro Biopharma, Inc., a Delaware corporation (“Subtenant”).